27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Semantic cognition requires a combination of semantic representations and executive control processes to direct activation in a task- and time-appropriate fashion [Jefferies, E., & Lambon Ralph, M. A. Semantic impairment in stroke aphasia versus semantic dementia: A case-series comparison. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Cerebral small vessel disease (SVD) is a major cause of stroke and dementia. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
The direct visualization of retinal vessels provides a unique opportunity to study cerebral small vessel disease, because these vessels share many features. 2 key findings →
Design: cohort study Participants: 490 Evidence: moderate
Full summary, score breakdown and related studies → Original source
We investigated the nature of the relationship between depression and vascular diseases by reviewing epidemiological, clinical, neuroimaging and neuropathology studies which have reported on the relationship of depression to coronary artery disease, stroke disease, alterations in blood pressure, vascular dementia, diabetes mellitus and cholesterol levels and by reviewing potential mechanisms by which depression could be associated with vascular diseases. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
It is associated with metabolic syndrome, incident diabetes, carotid atherosclerosis, and endothelial dysfunction, conditions that in turn are strongly linked with brain damage and cognitive impairment. 5 key findings →
Design: cross-sectional Participants: 766 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Genetic variants within the VCAN gene may play a role in the mechanisms underlying microstructural integrity of the white matter in the brain measured as FA and MD. 4 key findings →
Design: cohort study Participants: 8,448 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of WMLs. 2 key findings →
Participants: 123 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
White matter hyperintensities (WMHs) in the brain are the consequence of cerebral small vessel disease, and can easily be detected on MRI. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Acceleration in WMH burden, a common indicator of cerebrovascular disease in the elderly, is a pathologic change that emerges early in the presymptomatic phase leading to MCI. 2 key findings →
Design: longitudinal study Participants: 134 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Baseline DBP and longitudinal increases in DBP were independently associated with a greater WMHV, and the association between DBP and WMHV was greatest among blacks. 4 key findings →
Design: longitudinal study Participants: 1,281 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
White matter lesions are frequently found on cerebral MRI scans of elderly people and are thought to be important in the pathogenesis of dementia. 5 key findings →
Design: cross-sectional Participants: 1,077 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Aortic stiffness increases with age and vascular risk factor exposure and is associated with increased risk for structural and functional abnormalities in the brain. 5 key findings →
Participants: 668 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Higher levels of VRFs were associated with poorer brain health across grey and white matter macrostructure and microstructure. 5 key findings →
Participants: 9,722 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We postulated that cerebral amyloid angiopathy (CAA), characterised by cortical vascular amyloid deposits, is associated with cortical tissue loss independent of parenchymal Alzheimer's disease pathology. 4 key findings →
Design: case-control study Participants: 63 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Thirty percent of the cases had significant cerebrovascular parenchymal pathology scores (CVDPS), 54% had significant AD pathology, and 18% had HS. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Based on the title and abstracts, 830 papers were screened from which 250 primary research papers met the eligibility criteria (original research articles with patients or with a strict diabetes model without comorbidities, that included direct data about microglia in the brain or retina), and 17 additional research papers were included through forward and backward citations, resulting in a total of 267 primary research articles included in the scoping systematic review. 5 key findings →
Design: systematic review Participants: 267 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Regular voluntary exercise has been shown to increase waste transport through the glymphatic system in mice. 4 key findings →
Design: cohort Evidence: preliminary
Full summary, score breakdown and related studies → Original source Free full text
This should be considered when designing protocols for amyloid-modifying clinical trials. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
New consensus diagnostic criteria for TES were developed with a primary goal of facilitating future CTE research. 2 key findings →
Participants: 298 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Aging-associated WMHs evolve significantly over a 4-year period. 5 key findings →
Design: longitudinal study Participants: 150 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Cerebral microbleeds (CMBs) are increasingly recognised neuroimaging findings in individuals with cerebrovascular disease and dementia, and in normal ageing. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Microbleed prevalence was 15.3% (median [interquartile range] count, 1 [1-88]). 5 key findings →
Participants: 4,841 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Graph theoretical analysis of the speech/language network showed that regions with shorter functional paths to the epicentre exhibited greater longitudinal atrophy. 4 key findings →
Design: longitudinal study Participants: 30 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Cerebral small vessel disease is a major cause of stroke and dementia, but its genetic basis is incompletely understood. 4 key findings →
Participants: 42,310 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Portable, low‐field imaging could be useful for identifying moderate to severe WMHs. 4 key findings →
Design: prospective cohort Participants: 33 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
9 of the 903 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →